New drugs for methicillin-resistant Staphylococcus aureus: An update

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1465-1470

  Kumar, Krishan ^a   Chopra, Sidharth ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antibiotics; Mechanism of action; MRSA

Indexed keywords

ACH 702; AFN 1252; ANTIINFECTIVE AGENT; AVAROFLOXACIN; BRILACIDIN; CG400549; DALBAVANCIN; DAPTOMYCIN; DELAFLOXACIN; ERAVACYCLINE; FAB 001; FINAFLOXACIN; GSK1322322; ICLAPRIM; ISONIAZID; LINEZOLID; MX 2401; NADIFLOXACIN; OMADACYCLINE; ORITAVANCIN; PLAZOMICIN; PYROPHOSPHATE; RADEZOLID; SANGUINARINE; TD 1792; TEDIZOLID; TEICOPLANIN; TRICLOSAN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WCK771; XF 73;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOSYNTHESIS; CELL MEMBRANE; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG POTENCY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DEPOLARIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; SKIN INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84879468910     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt045     Document Type: Article

References (75)

1. Appelbaum PC. Microbiology of antibiotic resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45 Suppl 3: S165-70.
2. Jevons MP. Celbenin-resistant staphylococci. Br Med J 1961; 1: 124-5. 3 Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42 Suppl 1: S5-12.
3. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42 Suppl 1: S5-12.
4. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
5. Infectious Diseases Society of America. The 10×'20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3.
6. Craig WA, Andes DR, Stamstad T. In vivo pharmacodynamics of new lipopeptide MX-2401. Antimicrob Agents Chemother 2010; 54: 5092-8.
7. Rubinchik E, Schneider T, Elliott M et al. Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. Antimicrob Agents Chemother 2011; 55: 2743-54.
8. Hashizume H, Sawa R, Harada S et al. Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate. Antimicrob Agents Chemother 2011; 55: 3821-8.
9. Kahne D, Leimkuhler C, Lu W et al. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 2005; 105: 425-48.
10. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005; 55 Suppl 2: ii15-20.
11. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract 2007; 61: 853-63.
12. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-15.
13. Mendes RE, Woosley LN, Farrell DJ et al. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrob Agents Chemother 2012; 56: 1639-42.
14. Kim SJ, Cegelski L, Stueber D et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008; 377: 281-93.
15. Kim SJ, Cegelski L, Preobrazhenskaya M et al. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance. Biochemistry 2006; 45: 5235-50.
16. Belley A, Neesham-Grenon E, McKay G et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009; 53: 918-25.
17. Dunbar LM, Milata J, McClure T et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011; 55: 3476-84.
18. Pallanza R, Berti M, Goldstein BP et al. Teichomycin: in vitro and in vivo evaluation in comparison with other antibiotics. J Antimicrob Chemother 1983; 11: 419-25.
19. Somma S, Gastaldo L, Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother 1984; 26: 917-23.
20. Van Hal SJ, Paterson DL. New Gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis 2011; 24: 515-20.
21. Leuthner KD, Vidaillac C, Cheung CM et al. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates. Antimicrob Agents Chemother,2010;54:3799-3803.
22. Blais J, Lewis SR, Krause KM et al. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother 2012; 56: 1584-7.
23. Stryjewski ME, Potgieter PD, Li YP et al. TD-1792 versus vancomycin for the treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56: 5476-83.
24. PolyMedix. Brilacidin (PMX-30063). http://www.polymedix.com/pipeline/Brilacidin (27 November 2012, date last accessed).
25. 25 Farrell DJ, Robbins M, Rhys-WilliamsWet al. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. Int J Antimicrob Agents 2010; 35: 531-6.
26. Ooi N, Miller K, Randall C et al. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J Antimicrob Chemother 2010; 65: 72-8.
27. Farrell DJ, Robbins M, Rhys-Williams W et al. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob Agents Chemother 2011; 55: 1177-81.
28. Obiang-Obounou BW, Kang OH, Choi JG et al. The mechanism of action of sanguinarine against methicillin-resistant Staphylococcus aureus. J Toxicol Sci 2011; 36: 277-83.
29. Ippolito JA, Kanyo ZF, Wang D et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 2008; 51: 3353-6.
30. Shaw KJ, Poppe S, Schaadt R et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52: 4442-7.
31. Lawrence L, Danese P, DeVito J et al. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother 2008; 52: 1653-62.
32. Locke JB, Finn J, Hilgers M et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010; 54: 5337-43.
33. Prokocimer P, Bien P, Surber J et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55: 583-92.
34. ClinicalTrials.gov. TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). NCT01170221. 2011. http://www.clinicaltrials.gov/ct2/show/NCT01170221?term=TR-701&rank=4 (27 November 2012, date last accessed).
35. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011; 1241: 48-70.
36. Grossman TH, Starosta AL, Fyfe C et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012; 56: 2559-64.
37. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 2011; 1241: 122-52.
38. Noel GJ, Draper MP, Hait H et al. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56: 5650-4.
39. ClinicalTrials.gov. Study to Compare the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI). NCT00865280. 2009. http://www.clinicaltrials.gov/ct2/show/NCT00865280?term=PTK-0796&rank=1 (27 November 2012, date last accessed); Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI). NCT00876850. 2012. http://www.clinicaltrials.gov/ct2/show/NCT00876850?term=PTK-0796&rank=2 (27 November 2012, date last accessed).
40. Xiao XY, Hunt DK, Zhou J et al. Fluorocyclines. 1. 7-Fluoro-9- pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 2012; 55: 597-5.
41. ClinicalTrials.gov. Study to Compare TP-434 and Ertapenem in CA Complicated Intra-abdominal Infections. NCT01265784. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01265784?term=TP-434&rank=1 (27 November 2012, date last accessed).
42. Dozzo P, Moser HE. New aminoglycoside antibiotics. Expert Opin Ther Pat 2010; 20: 1321-41.
43. Tenover FC, Tickler I, Armstrong ES et al. Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int J Antimicrob Agents 2011; 38: 352-4.
44. ClinicalTrials.gov. Study for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. NCT01096849. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01096849?term=ACHN-490&rank=5 (27 November 2012, date last accessed).
45. Margolis PS, Hackbarth CJ, Young DC et al. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 2000; 44: 1825-31.
46. Ross JE, Scangarella-Oman NE, Miller LA et al. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J Clin Microbiol 2011; 49: 3928-30.
47. ClinicalTrials.gov. GSK1322322 versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection. NCT01209078. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01209078?term=GSK1322322&rank=4 (27 November 2012, date last accessed).
48. Kampranis SC, Maxwell A. Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem 1998; 273: 22606-14.
49. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.
50. Lemaire S, Kosowska-Shick K, Appelbaum PC et al. Activity of moxifloxacin against intracellular community-acquired methicillinresistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. J Antimicrob Chemother 2011; 66: 596-7.
51. Remy JM, Tow-Keogh CA, McConnell TS et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 2012; 67: 2814-20.
52. Nilius AM, Shen LL, Hensey-Rudloff D et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 2003; 47: 3260-9.
53. Rib-X Pharmaceuticals. Delafloxacin. http://www.rib-x.com/pipeline/delafloxacin.php#development (27 November 2012, date last accessed).
54. Stubbings W, Leow P, Yong GC et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother 2011; 55: 4394-7.
55. Idelevich EA, Kriegeskorte A, Stubbings W et al. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes. J Antimicrob Chemother 2011; 66: 2809-13.
56. Patel MV, De Souza NJ, Gupte SV et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother 2004; 48: 4754-61.
57. Bhagwat SS, McGhee P, Kosowska-Shick K et al. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob Agents Chemother 2009; 53: 811-3.
58. Jacobs MR, Appelbaum PC. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Exp Opin Pharmacother 2006; 7: 1957-66.
59. Farrell DJ, Liverman LC, Biedenbach DJ et al. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcusaureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother 2011; 55: 3631-4.
60. Fernandez J, Hilliard JJ, Morrow BJ et al. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. Antimicrob Agents Chemother 2011; 55: 5522-8.
61. Covington P, Davenport JM, Andrae D et al. Randomized, double-blind, Phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 2011; 55: 5790-7.
62. Pucci MJ, Podos SD, Thanassi JA et al. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother 2011; 55: 2860-71.
63. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003; 13: 4217-21.
64. Oefner C, Bandera M, Haldimann A et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 2009; 63: 687-98.
65. Oefner C, Parisi S, Schulz H et al. Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta Crystallogr D Biol Crystallogr 2009; 65: 751-7.
66. Krievins D, Brandt R, Hawser S et al.Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother 2009; 53: 2834-40.
67. Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs 2004; 5: 146-53.
68. Balemans W, Lounis N, Gilissen R et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 2010; 463: E3.
69. Payne DJ, Miller WH, Berry V et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother 2002; 46: 3118-24.
70. Karlowsky JA, Kaplan N, Hafkin B et al. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother 2009; 53: 3544-8.
71. Kaplan N, Albert M, Awrey D et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother 2012; 56: 5865-74.
72. ClinicalTrials.gov. A Study of Safety, Tolerability, and Efficacy of AFN-1252 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci. NCT01519492. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01519492?term=AFN-12520000&rank=1 (27 November 2012, date last accessed).
73. Escaich S, Prouvensier L, Saccomani M et al. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother 2011; 55: 4692-7.
74. Kim BY, Sohn YT. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation. Arch Pharm Res 2011; 34: 775-9.
75. Park HS, Yoon YM, Jung SJ et al. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 2007; 60: 568-4.